<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39207948</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study.</ArticleTitle><Pagination><StartPage>e1004377</StartPage><MedlinePgn>e1004377</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1004377</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1004377</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stroke prevention guidance for patients with atrial fibrillation (AF) uses evidence generated from randomised controlled trials (RCTs). However, applicability to patient groups excluded from trials remains unknown. Real-world patient data provide an opportunity to evaluate outcomes in a trial analogous population of direct oral anticoagulants (DOACs) users and in patients otherwise excluded from RCTs; however, there remains uncertainty on the validity of methods and suitability of the data. Successful reference trial emulation can support the generation of evidence around treatment effects in groups excluded or underrepresented in trials. We used linked United Kingdom primary care data to investigate whether we could emulate the pivotal ARISTOTLE trial (apixaban versus warfarin) and extend the analysis to investigate the impact of warfarin time in therapeutic range (TTR) on results.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">Patients with AF in the UK Clinical Practice Research Datalink (CPRD Aurum) prescribed apixaban or warfarin from 1 January 2013 to 31 July 2019 were selected. ARISTOTLE eligibility criteria were applied to this population and matched to the RCT apixaban arm on baseline characteristics creating a trial-analogous apixaban cohort; this was propensity-score matched to warfarin users in the CPRD Aurum. ARISTOTLE outcomes were assessed using Cox proportional hazards regression stratified by prior warfarin exposure status during 2.5 years of patient follow-up and results benchmarked against the trial results before treatment effectiveness was further evaluated based on (warfarin) TTR. The dataset comprised 8,734 apixaban users and propensity-score matched 8,734 warfarin users. Results [hazard ratio (95% confidence interval)] confirmed apixaban noninferiority for stroke or systemic embolism (SE) [CPRD 0.98 (0.82,1.19) versus trial 0.79 (0.66,0.95)] and death from any cause [CPRD 1.03 (0.93,1.14) versus trial 0.89 (0.80,0.998)] but did not indicate apixaban superiority. Absolute event rates for stroke/SE were similar for apixaban in CPRD Aurum and ARISTOTLE (1.27%/year), whereas a lower event rate was observed for warfarin (CPRD Aurum 1.29%/year, ARISTOTLE 1.60%/year). Analysis by TTR suggested similar effectiveness of apixaban compared with poorly controlled warfarin (TTR &lt; 0.75) for stroke/SE [0.91 (0.73, 1.14)], all-cause death [0.94 (0.84, 1.06)], and superiority for major bleeding [0.74 (0.63, 0.86)]. However, when compared with well-controlled warfarin (TTR ≥ 0.75), apixaban was associated with an increased hazard for all-cause death [1.20 (1.04, 1.37)], and there was no significant benefit for major bleeding [1.08 (0.90, 1.30)]. The main limitation of the study's methodology are the risk of residual confounding, channelling bias and attrition bias in the warfarin arm, and selection bias and misclassification in the analysis by TTR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Analysis of noninterventional data generated results demonstrating noninferiority of apixaban versus warfarin consistent with prespecified benchmarking criteria. Unlike in ARISTOTLE, superiority of apixaban versus warfarin was not seen, possible due to the lower proportion of Asian patients and higher proportion of patients with well-controlled warfarin compared to ARISTOTLE. This methodological template can be used to investigate treatment effects of oral anticoagulants in patient groups excluded from or underrepresented in trials and provides a framework that can be adapted to investigate treatment effects for other conditions.</AbstractText><CopyrightInformation>Copyright: © 2024 Powell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Emma Maud</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-9427-9468</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gungabissoon</LastName><ForeName>Usha</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-2040-1763</Identifier><AffiliationInfo><Affiliation>Epidemiology, GSK, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tazare</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7194-2615</Identifier><AffiliationInfo><Affiliation>Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smeeth</LastName><ForeName>Liam</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9168-6022</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baptiste</LastName><ForeName>Paris J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-2565-8525</Identifier><AffiliationInfo><Affiliation>Clinical Effectiveness Group, Centre for Primary Care, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bin Hammad</LastName><ForeName>Turki M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0009-0004-2812-7086</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Methodology and biostatistics team, Department of Efficacy and Safety, Drug sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Angel Y S</ForeName><Initials>AYS</Initials><Identifier Source="ORCID">0000-0002-8618-7333</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Ian J</ForeName><Initials>IJ</Initials><Identifier Source="ORCID">0000-0002-8970-1406</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wing</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2335-9641</Identifier><AffiliationInfo><Affiliation>Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>3Z9Y7UWC1J</RegistryNumber><NameOfSubstance UI="C522181">apixaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Using real world evidence to complement evidence from randomized controlled trials on oral anticoagulants for stroke prevention.</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="Y">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="Y">Pyridones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="Y">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>EMP was funded by a Medical Research Council studentship for this work, and is an employee of and holds stock in Compass Pathways outside the submitted work. UG is an employee of and holds stock in GSK. JT reports no conflict of interest and is supported by an unrestricted grant from GSK. LS reports grants from Wellcome, MRC, NIHR, BHF, Diabetes UK, ESRC, EU and GSK, personal fees from GSK and AstraZeneca, and is a trustee of the British Heart Foundation, outside the submitted work. PJB is supported by Barts Charity (MGU0504) and was supported by a GSK studentship at the time of writing. TBH reports no conflict of interest. AW reports no conflict of interest and is supported by a fellowship from British Heart Foundation (FS/19/19/34175). IJD reports grants, and holds stocks in GSK, outside the submitted work. KW has nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>13</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39207948</ArticleId><ArticleId IdType="pmc">PMC11361421</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1004377</ArticleId><ArticleId IdType="pii">PMEDICINE-D-23-02702</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adderley NJ, Ryan R, Nirantharakumar K, Marshall T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019;105(1):27–33. doi: 10.1136/heartjnl-2018-312977</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2018-312977</ArticleId><ArticleId IdType="pubmed">29991504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988. doi: 10.1161/01.str.22.8.983</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.22.8.983</ArticleId><ArticleId IdType="pubmed">1866765</ArticleId></ArticleIdList></Reference><Reference><Citation>Friberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke.Stroke. 2014;45(9):2599–2605. doi: 10.1161/STROKEAHA.114.006070</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.006070</ArticleId><ArticleId IdType="pubmed">25034713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AN, Abdelhafiz A. Clinical and Economic Implications of AF Related Stroke. J Atr Fibrillation. 2016;8(5):1279. doi: 10.4022/jafib.1279</Citation><ArticleIdList><ArticleId IdType="doi">10.4022/jafib.1279</ArticleId><ArticleId IdType="pmc">PMC5089483</ArticleId><ArticleId IdType="pubmed">27909470</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40(4):227–39. doi: 10.1159/000343667</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343667</ArticleId><ArticleId IdType="pubmed">23364221</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. 053 Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm. Heart. 2012;98:A32. doi: 10.1136/heartjnl-2012-301877b.53</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2012-301877b.53</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. doi: 10.1056/NEJMoa1107039</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107039</ArticleId><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report Eliquis apixaban. Procedure No.:EMEA/H/C/002148/X/04/G. EMA/641505/2012, 2012, page 35. Available from: https://www.ema.europa.eu/en/documents/variation-report/eliquis-h-c-2148-x-0004-g-epar-assessment-report-extension_en.pdf</Citation></Reference><Reference><Citation>National Institute for Health and Clinical Excellence. Premeeting briefing. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. Issue date: November 2012. Available from: https://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-premeeting-briefing2</Citation></Reference><Reference><Citation>Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al.. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative. Circulation. 2021;143(10):1002–1013. doi: 10.1161/CIRCULATIONAHA.120.051718 Epub 2020 Dec 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.051718</ArticleId><ArticleId IdType="pmc">PMC7940583</ArticleId><ArticleId IdType="pubmed">33327727</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, et al.. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur Respir J. 2021. Mar 25;57(3):2001586. doi: 10.1183/13993003.01586-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01586-2020</ArticleId><ArticleId IdType="pmc">PMC8176192</ArticleId><ArticleId IdType="pubmed">33093119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahabreh IJ, Robins JM, Hernán MA. Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations. Epidemiology. 2020;31(5):614–619. doi: 10.1097/EDE.0000000000001231</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001231</ArticleId><ArticleId IdType="pubmed">32740470</ArticleId></ArticleIdList></Reference><Reference><Citation>Baptiste PJ, Wong AYS, Schultze A, Clase CM, Leyrat C, Williamson E, et al. Comparative effectiveness of ARB and ACEi for cardiovascular outcomes and risk of angioedema among different ethnic groups in England: an analysis in the UK Clinical Practice Research Datalink with emulation of a reference trial (ONTARGET). medRxiv [Preprint]. 2024. doi: 10.1101/2024.01.17.24301397</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.01.17.24301397</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell EM, Douglas IJ, Gungabissoon U, Smeeth L, Wing K. Real-world effects of medications for stroke prevention in atrial fibrillation: protocol for a UK population-based non-interventional cohort study with validation against randomized trial results. BMJ Open. 2021;11:e042947. doi: 10.1136/bmjopen-2020-04294</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-04294</ArticleId><ArticleId IdType="pmc">PMC8055153</ArticleId><ArticleId IdType="pubmed">33858866</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al.. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi: 10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose M, Beasley N. Center for Drug Evaluation and Research Application number: 202155Orig1s000 MEDICAL REVIEW(S). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm</Citation></Reference><Reference><Citation>Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, et al.. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015;36(46):3268–3275. doi: 10.1093/eurheartj/ehv447</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv447</ArticleId><ArticleId IdType="pubmed">26371113</ArticleId></ArticleIdList></Reference><Reference><Citation>Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, et al.. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864–1872. doi: 10.1093/eurheartj/ehu046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu046</ArticleId><ArticleId IdType="pmc">PMC4104493</ArticleId><ArticleId IdType="pubmed">24561548</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacus SM, King G, Porro G. Causal Inference without Balance Checking: Coarsened Exact Matching Political Analysis. 2012;20(1):1–24. doi: 10.1093/pan/mpr013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pan/mpr013</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459–468. doi: 10.1002/pds.4107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4107</ArticleId><ArticleId IdType="pubmed">27610604</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster-Clark M, Mavros P, Garry EM, Stürmer T, Shmuel S, Young J, et al.. Alternative analytic and matching approaches for the prevalent new-user design: A simulation study. Pharmacoepidemiol Drug Saf. 2022;31(7):796–803. doi: 10.1002/pds.5446</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5446</ArticleId><ArticleId IdType="pubmed">35505471</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P.C. (2009), Some methods of propensity-score matching had superior performance to others: results of an empirical Investigation and Monte Carlo simulations. Biom J. 2009;51(1): 171–84. doi: 10.1002/bimj.200810488</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bimj.200810488</ArticleId><ArticleId IdType="pubmed">19197955</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodfield R, Grant I, UK Biobank Stroke Outcomes Group, UK Biobank Follow-Up and Outcomes Working Group, Sudlow CL. Accuracy of Electronic Health Record Data for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK Biobank Stroke Outcomes Group. PLoS ONE. 2015;10(10):e0140533. doi: 10.1371/journal.pone.0140533</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0140533</ArticleId><ArticleId IdType="pmc">PMC4619732</ArticleId><ArticleId IdType="pubmed">26496350</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P.C, Small DS. The use of bootstrapping when using propensity-score matching without replacement: A simulation study. Stat Med. 2014;33(24):4306–4319. doi: 10.1002/sim.6276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6276</ArticleId><ArticleId IdType="pmc">PMC4260115</ArticleId><ArticleId IdType="pubmed">25087884</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadie A., Spiess J. Robust Post-Matching Inference. J Am Stat Assoc, 2022;117(538)983–995. doi: 10.1080/01621459.2020.1840383</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.2020.1840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res SocialAdm Pharm. 2006;2(1):143–151. doi: 10.1016/j.sapharm.2005.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2005.12.001</ArticleId><ArticleId IdType="pubmed">17138506</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55. doi: 10.1093/biomet/70.1.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake HA, Leyrat C, Mansfield KE, Seaman S, Tomlinson LA, Carpenter J, et al.. Propensity scores using missingness pattern information: a practical guide. Stat Med. 2020;39(11):1641–1657. doi: 10.1002/sim.8503</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8503</ArticleId><ArticleId IdType="pmc">PMC7612316</ArticleId><ArticleId IdType="pubmed">32103533</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505 doi: 10.1136/bmj.k2505 Erratum in: BMJ. 2018 Oct 18;363:k4413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k2505</ArticleId><ArticleId IdType="pmc">PMC6031213</ArticleId><ArticleId IdType="pubmed">29973392</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;16(353):i3189. doi: 10.1136/bmj.i3189</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i3189</ArticleId><ArticleId IdType="pmc">PMC4910696</ArticleId><ArticleId IdType="pubmed">27312796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al.. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117(6):1072–1082. doi: 10.1160/TH17-01-0068</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH17-01-0068</ArticleId><ArticleId IdType="pmc">PMC6291856</ArticleId><ArticleId IdType="pubmed">28300870</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018;49(1):98–106. doi: 10.1161/STROKEAHA.117.018395</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.117.018395</ArticleId><ArticleId IdType="pubmed">29167388</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin J, Brigham and Women’s Hospital. Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04593030</Citation></Reference><Reference><Citation>Wang SV, Schneeweiss S, RCT-DUPLICATE initiative, Franklin JM, Desai RJ, Feldman W, et al.. Emulation of Randomized Clinical Trials With Nonrandomized Databse Analyses: Results of 32 Clinical Trials. JAMA. 2023;329(16):1376–1385. doi: 10.1001/jama.2023.4221</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.4221</ArticleId><ArticleId IdType="pmc">PMC10130954</ArticleId><ArticleId IdType="pubmed">37097356</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al.. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170(1):141–148.e1. doi: 10.1016/j.ahj.2015.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2015.03.017</ArticleId><ArticleId IdType="pubmed">26093875</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al.. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA. 2017;318(13):1250–1259. doi: 10.1001/jama.2017.13883</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.13883</ArticleId><ArticleId IdType="pmc">PMC5818856</ArticleId><ArticleId IdType="pubmed">28973247</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer JK, Li Y, Gu X, Souphis NM, Haymart B, Kline-Rogers E, et al.. Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. JAMA Intern Med. 2019;179(4):533–541. doi: 10.1001/jamainternmed.2018.7816</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.7816</ArticleId><ArticleId IdType="pmc">PMC6450296</ArticleId><ArticleId IdType="pubmed">30830172</ArticleId></ArticleIdList></Reference><Reference><Citation>Almas T, Musheer A, Ejaz A, Shaikh FN, Paracha AA, Raza F, et al.. Efficacy and safety of direct oral anticoagulants with and without Aspirin: A systematic review and Meta-analysis. Int J Cardiol Heart Vasc. 2022;40:101016. doi: 10.1016/j.ijcha.2022.101016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2022.101016</ArticleId><ArticleId IdType="pmc">PMC8958538</ArticleId><ArticleId IdType="pubmed">35355928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol. 2014;11(5):290–303. doi: 10.1038/nrcardio.2014.22</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2014.22</ArticleId><ArticleId IdType="pubmed">24614113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park S-J, Kim MH, et al.. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost. 2021;121(4):422–432. doi: 10.1055/s-0040-1718729</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1718729</ArticleId><ArticleId IdType="pubmed">33171520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillott RG, Willan K, Kain K, Sivananthan UM, Tayebjee MH. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace. 2017;19(3):356–363. doi: 10.1093/europace/euw010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euw010</ArticleId><ArticleId IdType="pubmed">26941337</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiekh SI, Harley M, Ghosh RE, Ashworth M, Myles P, Booth HP, et al.. Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom’s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES). Popul Health Metr. 2023;21:3. doi: 10.1186/s12963-023-00302-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12963-023-00302-0</ArticleId><ArticleId IdType="pmc">PMC10013294</ArticleId><ArticleId IdType="pubmed">36918866</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Benedetto V, Gichuru P, Burnell J, Antoniou S, Schilling RJ, et al.. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119–126. doi: 10.1136/heartjnl-2019-315307</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-315307</ArticleId><ArticleId IdType="pmc">PMC6993026</ArticleId><ArticleId IdType="pubmed">31601729</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>